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Abstract
Dyslipidemia is related to the progression of atherosclerosis and is an important risk factor for acute coronary syndromes. Our 
objective was to determine the effect of rosuvastatin on myocardial necrosis in an experimental model of acute myocardial 
infarction (AMI). Male Wistar rats (8-10 weeks old, 250-350 g) were subjected to definitive occlusion of the left anterior descend-
ing coronary artery to cause AMI. Animals were divided into 6 groups of 8 to 11 rats per group: G1, normocholesterolemic 
diet; G2, normocholesterolemic diet and rosuvastatin (1 mg·kg-1·day-1) 30 days after AMI; G3, normocholesterolemic diet and 
rosuvastatin (1 mg·kg-1·day-1) 30 days before and after AMI; G4, hypercholesterolemic diet; G5, hypercholesterolemic diet 
and rosuvastatin (1 mg·kg-1·day-1) 30 days after AMI; G6, hypercholesterolemic diet and rosuvastatin (1 mg·kg-1·day-1) 30 
days before and after AMI. Left ventricular function was determined by echocardiography and percent infarct area by histol-
ogy. Fractional shortening of the left ventricle was normal at baseline and decreased significantly after AMI (P < 0.05 in all 
groups), being lower in G4 and G5 than in the other groups. No significant difference in fractional shortening was observed 
between G6 and the groups on the normocholesterolemic diet. Percent infarct area was significantly higher in G4 than in G3. 
No significant differences were observed in infarct area among the other groups. We conclude that a hypercholesterolemic 
diet resulted in reduced cardiac function after AMI, which was reversed with rosuvastatin when started 30 days before AMI. A 
normocholesterolemic diet associated with rosuvastatin before and after AMI prevented myocardial necrosis when compared 
with the hypercholesterolemic condition.
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Dyslipidemia has been known to result in the progres-
sion of atherosclerosis and in an increased incidence of 
thrombotic complications in patients with coronary artery 
disease (CAD) (1). Many studies have shown that treatment 
of dyslipidemias is beneficial in decreasing the number of 
coronary events. However, the role of statins in myocardial 
protection after acute myocardial infarction (AMI) is not 
known. Experimental (2,3) and clinical studies (4,5) have 
demonstrated that coronary reperfusion in the setting of AMI 
reduces the extent of final necrosis and improves ventricular 
function, favorably influencing the late survival of infarcted 
patients (6). These effects seem to be independent of the 
efficiency of intervention (7). 
The statins, pharmacologically denominated as inhibi-
tors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) 
reductase, were developed in the 1970’s (8). Since then, 
new chemical structures of statins have been developed 
and have been widely used for the treatment of hypercho-
lesterolemia, reducing the levels of low-density lipoprotein 
cholesterol (LDL-C) and triglycerides (9). Some recently 
published studies have demonstrated that rosuvastatin 
is effective in reducing LDL-C levels and in increasing 
high-density lipoprotein cholesterol (HDL-C) (10,11), is 
safe in elderly patients with systolic cardiac dysfunction, 
and reduces the risk of cardiovascular events in healthy 
patients without dyslipidemia, but with high levels of high 
sensitivity C-reactive protein (12). Statins are also known 
to have pleiotropic effects, which seem to be independent 
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of their lipid-lowering action, such as anti-atherosclerotic, 
anti-inflammatory, anti-thrombosis, and anti-oxidant ef-
fects. These properties could potentially reduce the ne-
crotic area in the setting of AMI. However, the effects of 
rosuvastatin on myocardial necrosis have not been clearly 
demonstrated in the literature. 
Left ventricular dysfunction is the most frequent 
consequence of CAD and AMI. AMI frequently results in 
ventricular remodeling with dilation of the left ventricular 
cavity and wall thinning caused by mural stress (13). The 
development of heart failure after AMI is mainly caused 
by apoptosis and structural changes in myocardial tissue 
in reaction to metalloproteinase (MMP) enzymes (14,15). 
Moreover, pathological degradation of collagen after sev-
eral episodes of myocardial ischemia was associated with 
increased inflammatory activity in tissues and increased 
levels of angiotensin II and aldosterone, which are respon-
sible for ventricular remodeling (16,17).
The aim of this study was to evaluate the role of ro-
suvastatin on myocardial necrosis and cardiac function 
within the setting of experimental model of AMI. 
Material and Methods
The study was approved by the Institutional Review 
Board and performed in the Myocardial Ischemia Investi-
gation Laboratory of the Heart Institute (InCor), University 
of São Paulo Medical School. The protocol was in accor-
dance with the position of the American Heart Association 
Guidelines for Animal Research Use (18). 
We studied adult male Wistar rats weighing 250 to 
350 g, aged 8 to 10 weeks. Animals were maintained at 
22-24°C, 5 animals per cage, with free access to water. 
Animals assigned to the normocholesterolemic diet re-
ceived standard chow (Nuvital® from Nuvilab Nutrientes 
S/A, Brazil) while those assigned to the hypercholes-
terolemic diet received a special diet containing colic 
acid (19) (Table 1). Our goal with this procedure was to 
induce hypercholesterolemia in rats with a normal genetic 
background. All rats underwent a surgical procedure for 
definitive occlusion of the left anterior descending (LAD) 
coronary artery to cause AMI and were assigned to 6 
groups of 8-11 rats per group: G1, normocholesterolemic 
diet without rosuvastatin; G2, normocholesterolemic diet 
and rosuvastatin (1 mg·kg-1·day-1) 30 days after AMI; G3, 
normocholesterolemic diet and rosuvastatin (1 mg·kg-1·day-1) 
30 days before and 30 days after AMI; G4, hypercholes-
terolemic diet 30 days before and after AMI without rosu-
vastatin; G5, hypercholesterolemic diet 30 days before 
and after AMI and rosuvastatin (1 mg·kg-1·day-1) 30 days 
after AMI; G6, hypercholesterolemic diet 30 days before 
and 30 days after AMI and rosuvastatin (1 mg·kg-1·day-1) 
30 days before and 30 days after AMI.
The experimental protocol for each group is illustrated 
in Figure 1. 
Surgical procedure 
The animals were anesthetized with intraperitoneal 
xylazine (10 mg/kg) and ketamine (90 mg/kg). All surgi-
cal procedures were performed by the same operator, 
who was blind to animal group. An arterial cannula was 
inserted into the left ventricle to measure left ventricular 
end-diastolic pressure before and 5 min after AMI. The 
catheter position was confirmed by the characteristic 
pulse pressure. Left ventricular end-diastolic pressure 
was recorded beat-to-beat (DataQ Instruments, Inc., 
USA). The rats were mechanically ventilated (Harvard 
respirator, 2.5 mL, 75 to 80 strikes/min) and their chest 
wall was opened with a left thoracotomy. The LAD 
coronary artery was then permanently occluded with a 
5/0-silk thread close to its origin. After AMI, the animals 
were allowed to heal for 30 days.
Inflammatory markers
In all groups, blood samples were collected from the 
right jugular vein before and after LAD occlusion. Serum 
levels of tumor necrosis factor alpha (TNF-α), interleukin 
6 (IL-6), metalloproteinase 2 (MMP-2), and asymmetric 
dimethylarginine (ADMA) were determined by ELISA. 
Echocardiography
Echocardiography was performed using a com-
mercially available platform (HDI 5000, Philips Medical 
Systems, USA) equipped with a 12-MHz transducer. 
Echocardiographic imaging was adjusted to optimize 
image acquisition and echocardiographic parameters 
were then held constant for each experiment. The images 
were acquired at baseline, before LAD occlusion, and 
at 30 days after AMI. Left ventricular end-diastolic and 
end-systolic diameters were obtained by unidimensional 
Table 1. Composition of the hypercholesterolemic diet used in 
the intervention group.
Component Quantity (%) 
Carbohydrates* 51.95 
Protein† 20.00 
Lipids‡ 18.00 
Fibers 5.00 
Mineral mix 1.00 
Vitamin mix 3.00 
L-cystine 0.30 
Choline bitartrate 0.25 
Cholic acid 0.50 
*Carbohydrate fractions: 55.8% starch, 25.8% maltodextrin and 
18.4% sucrose. †Protein: commercial casein (85% protein). 
‡Lipid fraction: 66.7% coconut oil, 26.4% soybean oil and 6.9% 
cholesterol. Vitamin and mineral mixtures were based on the rec-
ommendations of the American Institute of Nutrition (AIN-93G). 
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Figure 1. Experimental protocol. AMI = acute myocardial infarction.
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mode at the level of papillary muscles. Fractional short-
ening was determined as the difference of end-diastolic 
and end-systolic diameters divided by end-diastolic 
diameter. Left ventricular volumes were determined 
by the biplane method of disks (Simpson’s rule). The 
myocardial thickness of the interventricular septum and 
inferoposterior wall of the left ventricle was measured 
and left ventricular mass was corrected by each animal’s 
body weight. Echocardiographic measurements were 
performed on all rats by the same investigator, who was 
blind to the animal groups.
Histology
After 30 days of AMI, rats were anesthetized with 
intraperitoneal xylazine (10 mg/kg) and ketamine (90 
mg/kg), and the left ventricle was cannulated with a 
needle for retrograde perfusion. 
The animals’ heart was arrested in diastole by perfu-
sion with 0.9% NaCl plus 14 mM KCl solution (pressure 
equal to a 13-cm water column), followed by buffered 
formalin for tissue fixation. Excised hearts were immersed 
in formalin for 24 h. The heart was then weighed on a pre-
cision scale (Mettler-Toledo AB104, Mettler-Toledo, USA). 
A median slice of the heart sectioned at the level of the 
papillary muscles was processed for microscopic analysis. 
Sections of 3 μm were stained with hematoxylin-eosin for 
qualitative assessment, and with Masson’s trichrome (blue 
stain) for quantification of the scar area. The left ventricular 
muscle area and interventricular septum thickness were also 
measured. Histomorphometric analyses were performed by 
the same person, who was blind to the treatment groups. 
Only one histological section was examined, and the healed 
infarction was delineated by computerized microscopy 
(Leica Imaging Systems, USA) (20) in order to calculate the 
percent area relative to the total area of the left ventricular 
myocardium. In fact, since the animals were kept alive for 
1 month after infarction, the fibrotic scar was measured. 
Statistical analysis
Quantitative data are reported as means ± SD. The 
variables measured in only one condition were evaluated 
by analysis of variance (ANOVA) with a classification factor, 
when significant. The Tukey test was applied to determine 
differences between groups. The variables, measured in 
more than one condition (pre- and post-AMI), were evaluated 
by ANOVA for repeated measures. Pre- and post-infarction 
biochemical levels were compared by the Wilcoxon sign 
test. Comparisons of all groups were performed using the 
Kruskal-Wallis test and if there were intergroup differences 
the Dunn test was applied. The level of significance was 
set at P < 0.05. 
Results
A total of 63 animals were initially enrolled in the study. 
Nine animals died during the surgical procedure (a mor-
tality rate of 14%) and 
a total of 54 animals 
completed the protocol: 
11 rats in G1; 8 rats in 
G2; 9 rats in G3; 10 rats 
in G4; 8 rats in G5, and 
8 rats in G6. Mean body 
weight was smaller in 
groups receiving the 
normocholesterolemic 
diet than in groups 
receiving the hypercho-
lesterolemic diet both at 
baseline and after 30 
days of AMI (Table 2). 
Similarly, end-diastolic 
left ventricular diame-
ters and volumes were 
smaller in animals who 
received the normocho-
lesterolemic diet than in 
those who received the 
hypercholesterolemic 
diet. No differences 
were observed in left 
ventricular mass cor-
rected by body weight 
Table 2. Characteristics of the animals in each treatment group.
G1 (N = 11) G2 (N = 8) G3 (N = 9) G4 (N = 10) G5 (N = 8) G6 (N = 8)
Baseline
Weight (g) 250 ± 22* 250 ± 40* 261 ± 33* 342 ± 31* 372 ± 25* 366 ± 18*
HR (bpm) 329 ± 45 310 ± 47 265 ± 22 310 ± 39 323 ± 33 275 ± 37
LVDD (mm) 5.8 ± 1.1∆ 5.2 ± 0.5∆ 6.5 ± 0.7∆ 6.1 ± 0.7∆ 6.3 ± 0.5∆ 6.5 ± 0.3∆
EDV (mL) 0.42 ± 0.21+ 0.3 ± 0.05+ 0.54 ± 0.12+ 0.53 ± 0.12+ 0.67 ± 0.09+ 0.72 ± 0.12+
EF (%) 0.81 ± 0.06 0.81 ± 0.03 0.79 ± 0.05 0.83 ± 0.04 0.78 ± 0.05 0.75 ± 0.03 
ILVM (g/kg) 1.32 ± 0.16 1.24 ± 0.19 1.35 ± 0.15 1.18 ± 0.20 1.14 ± 0.12 1.22 ± 0.11
30 days after AMI
Weight (g) 356 ± 33* 332 ± 42* 331 ± 39* 433 ± 44* 436 ± 55* 436 ± 54*
HR (bpm) 287 ± 36 300 ± 27 297 ± 34 293 ± 24 293 ± 24 295 ± 20
LVDD (mm) 8.3 ± 1.2∆ 7.7 ± 0.6∆ 7.6 ± 0.6∆ 8.6 ± 1.3∆ 8.6 ± 1.3∆ 8.4 ± 0.9∆ 
EDV (mL) 0.92 ± 0.25+ 0.84 ± 0.14+ 0.74 ± 0.11+ 1.15 ± 0.32+ 1.19 ± 0.28+ 1.22 ± 0.43+ 
EF (%) 0.46 ± 0.10 0.46 ± 0.09 0.44 ± 0.09 0.38 ± 0.12 0.38 ± 0.14 0.41 ± 0.14 
HW (g) 1.79 ± 0.27 1.68 ± 0.24 1.65 ± 0.15 1.78 ± 0.22 1.88 ± 0.13 1.82 ± 0.11
ILVM (g/kg) 1.71 ± 0.21 1.61 ± 0.22 1.76 ± 0.17 1.67 ± 0.21 1.66 ± 0.16 1.59 ± 0.15
Data are reported as means ± SD. See Figure 1 for protocol. HR = heart rate; LVDD = left ventricular 
diastolic diameter; EDV = end-diastolic volume; EF = left ventricular ejection fraction; ILVM = indexed left 
ventricular mass; HW = heart weight. *P < 0.05 G1, G2, G3 compared to G4, G5, G6 at baseline and also 
at 30 days after AMI (ANOVA). ∆P < 0.05 all groups at baseline compared to 30 days after AMI (ANOVA 
for repeated measures). +P < 0.05 all groups at baseline compared to 30 days after AMI (ANOVA for 
repeated measures).
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not change in the other groups (P = NS). 
After LAD occlusion, TNF-α levels were reduced in G1 
compared to G5 (P < 0.05), whereas no difference was 
observed in the other groups. Before LAD occlusion, ADMA 
levels were higher in G1 than in G3 and G5 and were reduced 
after LAD occlusion in G3 compared to G6 (P < 0.05).
and, after animals sacrifice, there was no difference in 
heart weight between groups. When compared to baseline, 
there was a significant increase in left ventricular diastolic 
diameter (P < 0.05) and left ventricular volume (P < 0.05) 
in all groups.
Figure 2 illustrates the fractional shortening in the 6 groups 
at baseline and 30 days after AMI. Fractional shortening was 
normal at baseline and decreased significantly after AMI (P 
< 0.05 in all groups). After AMI, fractional shortening was 
lower in groups 4 (hypercholesterolemic diet without rosu-
vastatin) and 5 (hypercholesterolemic diet with rosuvastatin 
after AMI) than in the other groups. No significant difference 
was observed in fractional shortening between group 6 
(hypercholesterolemic diet with rosuvastatin before and after 
AMI) and groups receiving the normocholesterolemic diet. 
Infarct size
Histological analysis revealed that the percentage of 
infarct area was significantly lower in G3 (normocholester-
olemic diet with rosuvastatin 30 days before and after AMI) 
than in G4 (hypercholesterolemic diet without rosuvastatin), 
as demonstrated in Figure 3. No significant differences were 
observed in infarct area among the other groups.
Biochemical analysis 
IL-6, MMP-2, TNF-α, and ADMA levels before and after 
LAD occlusion are presented in Table 3. At baseline, no 
difference was observed in IL-6 or TNF-α between groups. 
After LAD occlusion, IL-6 levels decreased in G1 compared 
to G2 (P < 0.05), whereas no difference was observed in 
the other groups. 
At baseline, MMP-2 levels were higher in G1 than in 
G3 and G5 (P < 0.05). MMP-2 levels were reduced after 
LAD occlusion in G5 compared to G2 (P < 0.05) and did 
Figure 2. Fractional shortening of left ventricle. See Figure 1 for 
protocol. There was significant decrease in fractional shortening 
from baseline to the post-acute myocardial infarction condition in 
all groups. The variables measured in only one condition were 
evaluated by analysis of variance (ANOVA) with a classification 
factor, when significant. The Tukey test was applied to determine 
differences between groups. AMI = acute myocardial infarction.
Figure 3. Percent infarct area determined by histological analysis. 
See Figure 1 for protocol. The data were compared between all 
groups. The variables measured in only one condition were evalu-
ated by analysis of variance (ANOVA) with a classification factor, 
when significant. The Tukey test was applied to determine differ-
ences between groups.
Table 3. Biochemical data at baseline and after left anterior de-
scending (LAD) coronary artery occlusion.
IL-6 
(pg/mL)
MMP-2 
(pg/mL)
TNF-α 
(pg/mL)
 ADMA 
(µM)
Baseline
G1 47.1 301.1* 0.00 1.21#
G2 43.9 268.7 0.07 1.23
G3 28.6 136.2* 0.06 0.73#
G4 11.7 162.4 0.36 0.93
G5 11.1 147.2* 0.08 0.77#
G6 53.4 169.5 0.08 0.81
30 days after AMI
G1 6.4* 188.8 0.36+ 0.85
G2 84.1* 186.5# 1.71 0.84
G3 26.9 153.2 0.00 0.72∆
G4 39.1 122.8 8.63 0.90
G5 66.1 103.0# 22.1+ 0.85
G6 23.2 132.5 19.2 1.01∆
Data are reported as median. See Figure 1 for protocol. IL-6 = 
interleukin 6; MMP-2 = metalloproteinase 2; TNF-α = tumor ne-
crosis factor alpha; ADMA = asymmetric dimethylarginine. Lev-
els were compared between pre- and post-infarction conditions. 
Baseline: *P < 0.05 G3, G5 compared to G1 (ANOVA). #P < 0.05 
G3, G5 compared to G1 (ANOVA). 30 days after AMI: *P < 0.05 
G1 compared to G2 (ANOVA). #P < 0.05 G5 compared to G2 
(ANOVA). +P < 0.05 G1 compared to G5 (ANOVA). ∆P < 0.05 G3 
compared to G6 (ANOVA).
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Discussion 
In this study, we demonstrated that a normocholester-
olemic diet associated with rosuvastatin 30 days before 
and 30 days after AMI resulted in a decreased percentage 
of myocardial necrosis area compared to a hypercho-
lesterolemic diet. Interestingly, the hypercholesterolemic 
diet resulted in depressed left ventricular systolic function 
after AMI and this effect was attenuated by treatment with 
rosuvastatin 30 days before and after AMI (but not by treat-
ment after AMI alone). We believe that these data would 
be of important benefit for the treatment of infarcts if these 
achievements were confirmed in human models. We know 
that, before extrapolating these data to clinical practice, it 
would be important to confirm them in experiments of longer 
duration to evaluate ventricular function and remodeling, 
and also in other animal models such as pig or dogs whose 
coronary system is closer to the human one.
According to Davignon and Laaksonen (21), statins 
have several effects related to the reduction of LDL-C 
levels. However, this class of drugs has other metabolic 
manifestations such as pleiotrophic effects that are inde-
pendent of cholesterol reduction. The fundamental question 
that remains is whether these effects promote additional 
cardioprotection than the known LDL-C-reducing action. 
Rosenson and Tangney (22) have suggested 4 non-lipidic 
mechanisms that may contribute to the beneficial effects 
on clinical events. These effects include modification of 
endothelial function, inflammatory response, plaque sta-
bilization, and thrombus formation.
Findings showing that pharmacological inhibition of 
MMP attenuates the dilation of the left ventricle in infarcted 
rats have led to the conclusion that the mechanisms of MMP 
inhibitors may have therapeutic potential in patients at risk 
of developing heart failure after AMI (23). In a retrospective 
study, Lagrand et al. (24) concluded that C-reactive protein 
is a marker of risk factors for cardiovascular disease based 
on still unknown molecular mechanisms. In a clinical study, 
Strandberg et al. (25) observed a significant decrease in 
C-reactive protein levels using atorvastatin and simvastatin 
for the treatment of dyslipidemia, as also observed in the 
CARE study (26).
Inflammatory cytokines secreted by macrophages and 
T lymphocytes may modify endothelial function and influ-
ence the proliferation of smooth muscle cells, degradation 
of collagen, and thrombosis (27). In an experimental study 
on dyslipidemic animals, Scalia et al. (28) observed an 
increased expression of P-selectin activity, the intercellular 
adhesion molecule (ICAM-1) and the adhesion molecule 
of vascular cell (VCAM-1) in the interaction of leukocytes 
with the endothelium. 
In clinical situations, such as hypercholesterolemia, 
the bioavailability of nitric oxide is reduced, among other 
factors, by increased levels of an endogenous competitive 
inhibitor of eNOS, ADMA, which assumes the function of 
regulating the formation of nitric oxide that preserves the 
important vascular tone (29). Serum ADMA levels were 
significantly higher in hypercholesterolemic individuals 
compared to normocholesterolemic individuals and the 
L-arginine/ADMA ratio was decreased in these patients 
(30).
Zoccali et al. (31) also pointed out the multifaceted 
origin of atherosclerosis, emphasizing that endothelial 
dysfunction, the initial insult, is characterized by increased 
adhesiveness of the endothelium to leukocytes and plate-
lets and the synthesis of molecules with vessel activity, 
cytokines and pro-coagulation factors. Cytokines, low 
molecular weight proteins involved in inflammation and in 
the responses of the immune system, are considered to be 
independent risk factors for coronary artery and cerebro-
vascular diseases (32). Among them are TNF-α, IL-6 and 
the inhibitor of plasminogen activator factor 1 (33).
In our study, we did not observe reduction of TNF-α, 
IL-6 or ADMA levels in the groups treated with rosuvas-
tatin. No correlation was observed between biochemical 
data and infarcted area size, showing no direct correlation 
between the biochemical expressions and hemodynamic 
repercussion of the infarct. However, we did demonstrate 
a reduction in infarcted area size in normocholesterolemic 
animals treated with rosuvastatin before AMI and dur-
ing the healing period. These data indicate the need for 
clinical studies to confirm whether the use of a statin by 
normocholesterolemic patients can reduce infarct size and 
improve ventricular function. 
Limitations
Infarct size using this model is not uniform, mainly 
because of the inability to occlude the coronary artery ex-
actly at the same point in all animals, as well as because 
of eventual anatomical variations. Since infarct area risk 
was not determined in our study, infarct size was reported 
as the percentage of total left ventricular area. 
Certainly there would be differences between coronary 
atherosclerosis and our model of infarction in rats without 
previous coronary artery disease, but the final mechanisms 
would be similar because acute vessel occlusion was 
provoked. We observed an increase in cholesterol levels 
in the groups on a hypercholesterolemic diet, but there 
were no significant differences in endothelial dysfunction 
evaluated by ADMA or in inflammatory biomarkers. The 
only difference observed was in MMP-2 levels, which 
were lower in the hypercholesterolemic group treated with 
rosuvastatin (G5), demonstrating a possible role of rosu-
vastatin in protecting against myocardial damage by some 
mechanism that causes less MMP-2 expression. This may 
lead to mural realignment of myocyte clusters and/or of 
individual myocytes within the left ventricular wall, causing 
thinning and dilation of the ventricular wall and consequent 
heart failure. Moreover, the pathological degradation of 
collagen after various myocardial episodes of ischemia 
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was associated with increased inflammatory activity in 
tissues and an increase of angiotensin II and aldosterone, 
which also provide the remodeling. Thus, the present data 
demonstrating a reduction in MMP-2 expression in the 
hypercholesterolemic group could be important for the 
evaluation of the development of ventricular remodeling. 
A hypercholesterolemic diet in rats resulted in reduced 
cardiac function after AMI, which was reversed by rosuvas-
tatin when started before AMI. A normocholesterolemic diet 
associated with rosuvastatin before and after AMI prevented 
myocardial necrosis compared to the hypercholesterolemic 
condition. 
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